5322962026-05-295322962026-05-292026-05-29532296Glenmark Pharmaceuticals LimitedGLENMARKNOTLISTEDINE935A01035NewSale or disposal of unit(s)/division(s)/subsidiarytrue2026-05-2919:26:002026-05-292026-06-012026-06-30CashThe brands/ IP portfolio transfer is expected to be carried out at a cash consideration of Rs. 223 Cr based on the Independent Valuer report.The buyer is Glenmark Healthcare Limited a wholly owned subsidiary of the Company, having its registered office at Glenmark House, B.D. Sawant Marg, Chakala, Andheri (East), Mumbai - 400099, India.trueThe buyer is the wholly owned subsidiary of the Company. Glenmark Healthcare Limited is engaged in manufacturing of pharmaceutical products.true2026-05-29falsetruefalseThe Nebulizer business segment is registering robust growth across India and Emerging Markets, offering a significant opportunity to scale. The Company aims to transfer the complete ownership of its Nebulizer brands/IP portfolio to GHL. GHL is in the process of setting up a new dedicated Nebulizers manufacturing facility wherein these products will be manufactured. The proposed structure will enable sharper strategic focus, greater operational agility, and long-term value creation for all stakeholders. The subsidiary will also house a portfolio of innovative Nebulizers including the world’s first nebulized triple therapy for Chronic Obstructive Pulmonary Disease (COPD), further consolidating Glenmark’s leadership in respiratory innovation and its commitment to making advanced, affordable, and accessible solutions for patients.